DB-2304 antibody injection for lupus skin disease (SLE/CLE)
Treatments studied
Part of Immune system & allergy, Skin clinical trials.
This trial tests an experimental antibody injection (DB-2304) to see if it can improve lupus skin rashes and other lupus symptoms. It is for people with active lupus skin disease who have already tried standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with Systemic Lupus Erythematosus (SLE) or Cutaneous Lupus Erythematosus (CLE) and currently have active skin lupus (rashes or sores).
- You must be between 18 and 70 years old.
- You have been on the same lupus medications for at least 1 month without changes.
- You do not have any active infections (like shingles, herpes, or an infection requiring antibiotics in the last 30 days).
- You have not had lupus affecting your kidneys (lupus nephritis) or brain (neuropsychiatric lupus).
- You do not have a history of certain cancers or other conditions that weaken your immune system.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental daily pill (BI 3000202) for people with active lupus (SLE) to see if it can reduce disease activity. It compares different doses against a placebo, and you must already be on stable lupus background treatment.
This trial tests a new treatment for people with active lupus who haven't responded well to steroids and at least two other immune-suppressing drugs, including a biologic. It aims to find a better option for controlling lupus symptoms.
This trial tests two new drugs, BCD-256-1 and divozilimab, for people with systemic lupus erythematosus (SLE) who have active skin symptoms not controlled by current treatments. The goal is to see if they are safe and how the body processes them.
This trial tests an investigational injection called CM313 for people with active lupus (systemic lupus erythematosus). It aims to see if the drug can help reduce lupus symptoms and control the disease.
This study tests a new injectable medicine (SG301) for people with lupus (SLE) whose current treatments are not working well enough or cause side effects. It aims to see if this targeted therapy can better control lupus symptoms.
This study tests a new investigational drug called SCTB35 for people with active systemic lupus erythematosus (SLE or lupus). It aims to see if the drug is safe and effective in controlling lupus activity when added to your current stable lupus medications.
Hear when a new Systemic Lupus Erythematosus (SLE) or Cutaneous Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.